Alnylam Pharmaceuticals General and Administrative Expenses 2011-2026 | ALNY

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Alnylam Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.21 B	976 M	796 M	771 M	621 M	588 M	479 M	382 M	199 M	89.4 M	60.6 M	44.5 M	27.2 M	43.7 M	38.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.21 B	27.2 M	422 M

Quarterly General and Administrative Expenses Alnylam Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
323 M	240 M	-	221 M	248 M	211 M	-	199 M	215 M	184 M	-	236 M	170 M	154 M	-	142 M	145 M	147 M	-	167 M	128 M	127 M	-	120 M	113 M	89.6 M	-	117 M	84.7 M	72.4 M	-	47.6 M	45.8 M	38.5 M	-	22.4 M	18 M	21.1 M	-	16 M	14.6 M	12.7 M	-	9.9 M	11.5 M	8.92 M	-	6.77 M	5.78 M	6.27 M	-	12.8 M	11.2 M	10.4 M	-	8.96 M	8.43 M	10.2 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
323 M	5.78 M	95.5 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
ADMA Biologics ADMA	91.6 M	$ 15.57	-5.89 %	$ 3.71 B	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
AbCellera Biologics ABCL	83.2 M	$ 3.58	-1.38 %	$ 1.07 B	Canada
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Anika Therapeutics ANIK	95.8 M	$ 14.19	-1.18 %	$ 208 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Aptorum Group Limited APM	5.41 M	$ 0.82	-0.73 %	$ 4.47 M	China
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Apellis Pharmaceuticals APLS	550 M	$ 20.24	1.91 %	$ 2.55 B	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	250 M	$ 75.6	-1.22 %	$ 1.46 B	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Autolus Therapeutics plc AUTL	46.7 M	$ 1.5	-8.28 %	$ 383 M	Britain
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Athersys ATHX	20.1 M	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
AVEO Pharmaceuticals AVEO	60.8 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	63.3 M	$ 159.87	-2.57 %	$ 7.95 B	USA
BridgeBio Pharma BBIO	531 M	$ 65.73	-1.22 %	$ 12.6 B	USA
Brainstorm Cell Therapeutics BCLI	7.04 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	5.72 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Equillium EQ	13.6 M	$ 1.79	2.29 %	$ 62.2 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	4.31 M	$ 2.72	-3.31 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	1.15 B	$ 60.54	0.18 %	$ 11.6 B	USA
Burford Capital Limited BUR	99.3 M	$ 8.26	-1.31 %	$ 1.36 B	Britain
Cabaletta Bio CABA	19.2 M	$ 3.2	-6.71 %	$ 3.74 M	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	78.7 M	$ 2.93	-8.44 %	$ 1.05 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Capricor Therapeutics CAPR	12.8 M	$ 25.74	0.94 %	$ 689 M	USA